Charles River Laboratories International, Inc. (CRL) — Fair Value Analysis
Base-case fair value (P50): $249.63 · Current price: $230.69 · Verdict: Fairly Valued
The Verdict on CRL
Charles River Laboratories (CRL) currently registers as Fairly Valued based on our proprietary Monte Carlo simulations. This rigorous analytical framework, assessing thousands of forward-looking scenarios for the Healthcare sector, indicates that CRL's median fair value (P50) stands at $249.63. Comparing this to the current trading price of $230.69, our model suggests a modest potential +8.2%. This verdict implies that, according to our simulations, CRL is trading close to its intrinsic value, making it neither significantly overvalued nor undervalued in the current market. Investors should therefore not expect substantial immediate mispricing.
How CRL stacks up against Healthcare
Within the competitive Healthcare sector, our analysis positions Charles River Laboratories with an average quality tier, reflecting its operational and financial health relative to its peers. This assessment of CRL's core fundamentals plays a critical role in shaping the outputs of our Monte Carlo simulations. The proximity of CRL's current trading price of $230.69 to our calculated median fair value of $249.63 suggests that the market has largely priced in the company's established position and its average performance characteristics within the Healthcare landscape. This alignment underscores the Fairly Valued assessment, suggesting market efficiency.
What this means for investors
For investors evaluating Charles River Laboratories, the Fairly Valued verdict signals a balanced risk-reward profile at its current price of $230.69. With the median fair value estimated at $249.63, presenting a +8.2% against market price, the stock isn't signaling a deep-value opportunity or a significant overvaluation risk through our primary P50 lens. While this indicates equilibrium, our comprehensive Monte Carlo analysis also models a full spectrum of potential upside and downside scenarios for CRL. To explore the complete distribution of probable outcomes and track CRL's evolving fair value as new financial data and market conditions emerge, sign up for a free FairCurve account.
Frequently Asked Questions
Is CRL overvalued or undervalued right now?
Based on our Monte Carlo simulations, Charles River Laboratories (CRL) is considered Fairly Valued, with its median fair value (P50) of $249.63 closely aligning with its current market price of $230.69.
What is the bear case and bull case for CRL?
Our comprehensive Monte Carlo simulations generate a full probability distribution of potential fair values for CRL, encompassing both bear (P10) and bull (P90) case targets. These detailed scenarios, including the probability of achieving upside, are exclusively available to users with a free FairCurve account.
How does FairCurve calculate CRL's fair value?
FairCurve calculates CRL's fair value through a sophisticated Monte Carlo simulation process, running thousands of forward-looking scenarios to determine a probabilistic range of intrinsic values. This approach provides a robust estimate by accounting for various market and fundamental uncertainties.
How can I track CRL's fair value as it changes?
You can add Charles River Laboratories (CRL) to your free FairCurve watchlist to receive daily updates on its fair value. FairCurve automatically re-values CRL instantly when new earnings reports or significant fundamental data are released.